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In Brief Roy et al. show that the cholesterollowering drugs statins increase the expression of neurotrophins in the brain by binding to the ligand-binding domain of PPARa, independent of the mevalonate pathway. Simvastatin also increases neurotrophin expression and improves memory and learning in a mouse model of Alzheimer's disease.
INTRODUCTION
Brain-derived neurotrophic factor (BDNF) and NT-3 are neurotrophins belonging to the NGF family of neuronal growth factors. BDNF infusion in the substantia nigra of rodent brain protects dopaminergic neurons, suggesting therapeutic prospects for Parkinson's disease. Moreover, the injection of BDNF in hippocampus and amygdaloid regions leads to the protection of cholinergic neurons (Morse et al., 1993) and improvement in cognitive impairment (Nagahara et al., 2009 ), implicating BDNF in Alzheimer's disease. BDNF is also capable of repairing spiny striatal interneurons in Huntington's disease (Kells et al., 2004) and remyelinating the lower motor neurons (Stadelmann et al., 2002) in multiple sclerosis. Therefore, BDNF promotes both structural and functional integrity of neurons to alleviate different neurological disorders. Similarly, NT-3 protects damaged neurons, stimulates neurogenesis and restores neuronal functions in the CNS affected by neurodegenerative diseases (Abe, 2000; Cheng and Mattson, 1994) . However, the mechanisms by which the production of these neurotrophins could be therapeutically increased in the CNS are poorly understood.
Although statins are cholesterol-lowering drugs, lovastatin inhibits the activation of NF-kB and the expression of proinflammatory molecules in brain cells via modulation of the mevalonate pathway, thus prompting investigation of the efficacy of statins as an anti-inflammatory and neuroprotective drug (Pahan et al., 1997) . Therefore, in addition to cholesterol-lowering, statins are currently known to control inflammation, attenuate cell proliferation and cell migration, favor vasodilation, modulate adaptive immunity, and suppress oxidative stress via modulation of the mevalonate pathway (Pahan, 2006; Roy and Pahan, 2011) . Here, we report that statins also exhibit a neurotrophic effect. Different statins upregulate BDNF and NT-3 in neurons, microglia, and astrocytes. Although most of the biological functions of statins depend on their ability to inhibit the mevalonate-cholesterol pathway, statins stimulate the expression of neurotrophins independently of this pathway. Interestingly, we have found that statins directly interact with two critical residues Leu331 and Tyr334 located in the ligand-binding domain of PPARa to regulate the transcription of CREB, leading to expression of neurotrophic molecules. Finally, we demonstrate that simvastatin increases BDNF and improves memory and learning in an animal model of Alzheimer's disease (AD) via PPARa.
RESULTS

Different Statins Induce the Expression of BDNF and NT-3 in Primary Glia and Neurons
Astrocytes are the predominant cell type in the CNS and we first investigated the effect of time-dependent effect of simvastatin on BDNF expression in astrocytes. Although simvastatin-mediated increase in BDNF mRNA was not visible at 2 hr, marked upregulation was observed at 5 hr of stimulation ( Figure S1A ). Accordingly, mevastatin, simvastatin, and pravastatin dosedependently upregulated the mRNA expression of BDNF and NT-3 in mouse primary astrocytes (Figures S1B and S1C) and microglia (Figures S1D and S1E) . Consistently, our protein results show upregulation of BDNF and NT-3 in both astrocytes and microglia by ELISA (Figures S1F and S1G) and immunocytochemistry (Figures S1H and S1I) . Similar to mouse astrocytes, mevastatin dose-dependently increased the mRNA (Figures S1J and S1K) and protein ( Figure S1L ) expression of BDNF in primary human astrocytes. Immunofluorescence analyses revealed that both astrocytes ( Figure S1M ) and microglia ( Figure S1N ) in the cortex of simvastatin-fed mice expressed higher levels of BDNF than the brain of saline-fed mice. These results demonstrate that statins are capable of stimulating BDNF and NT-3 in glial cells in culture as well as in vivo in the brain. Earlier, Wu et al. (2008) showed increase in BDNF in vivo in the brain by simvastatin.
While astrocytes and microglia produce neurotrophic factors under neurodegenerative conditions (Kerschensteiner et al., 1999; Roy et al., 2007) , neurons are major contributors of neurotrophic factors in normal brain (Maisonpierre et al., 1990) . Similar to glia, the different statins stimulated mRNA (Figures S1O and S1P) and protein expression (Figures S1Q and S1R) of neurotrophins in mouse cortical neurons. To further confirm, we knocked down the BDNF gene by small interfering (siRNA) (Figures S1S and S1T) and found that siRNA knock down of BDNF decreased the production of BDNF protein in simvastatin-treated cortical neurons ( Figure S1U ). Furthermore, glutamate significantly induced the production of BDNF in neurons ( Figure S1U ). Similar to mouse cells, different statins also dose-dependently stimulated the expression of neurotrophins in primary human neurons (Figures S1V and S1W). Accordingly, oral administration of simvastatin upregulated the neuronal expression of BDNF in the cortex compared with vehicle-fed mice ( Figure S1X ). Therefore, statins are also able to stimulate the expression of neurotrophic factors in neurons.
Statin-Induced Expression of BDNF and NT-3 Is Independent of the Mevalonate Pathway Next, we investigated the mechanism by which statins might upregulate the expression of neurotrophins in glia. Since statins selectively inhibit HMG-CoA reductase, most of the known biological functions of statins depend on their ability to modulate the mevalonate pathway (Endo et al., 1976; Pahan et al., 1997) . However, pretreatment with increasing doses of mevalonate and farnesyl pyrophosphate (FPP) failed to abrogate the statininduced mRNA expression of neurotrophins in astrocytes (Figures 1A and 1B) , suggesting that statins upregulate the expression of neurotrophic factors independently of mevalonate metabolites. By contrast, mevalonate, FPP, and geranylgeranyl pyrophosphate (GPP) dose-dependently abrogated simvastatin-mediated inhibition of iNOS in IL-1b-stimulated astrocytes ( Figures 1C and 1D) . Moreover, the selective inhibition of small G proteins by dominant-negative mutants of p21 ras (DRas) and p21 rac (DRac) failed to stimulate the mRNA expression of BDNF ( Figure 1E ). On the other hand, both DRas and DRac inhibited the IL-1b-induced mRNA expression of iNOS in astrocytes ( Figure 1F ). Consistent with this finding, while the siRNAmediated knockdown of p21 ras failed to increase the expression of BDNF in astrocytes ( Figure 1G ), it downregulated iNOS protein ( Figures 1H-1I ) expression. Farnesyl pyrophosphate transferase (FPT) transfers the farnesyl group to p21 ras , resulting in membrane attachment of p21 ras and its activation. It was previously reported that FPT inhibitor (FPTi) inhibited the downstream activation of various inflammatory pathways such as NF-kB (Pahan et al., 1997) . Interestingly, FPTi had no stimulatory effect on the mRNA expression of BDNF in astrocytes ( Figure 1J ), suggesting that the farnesylation-p21 ras pathway is not involved in the upregulation of neurotrophic factors. Similarly, geranylgeranyl transferase transfers the geranylgeranyl group to p21 rac for its membrane attachment and activation. Similar to FPTi, geranylgeranyl transferase inhibitor (GGTi) also failed to induce the mRNA expression of BDNF ( Figure 1J ), indicating that the geranylgeranylation-p21 rac pathway is also not involved in the stimulation of neurotrophic factors. However, as expected, both FPTi and GGTi suppressed the IL-1b-induced expression of iNOS in astrocytes (Figures 1K and 1L) . Taken together, these data suggest that statins employ two independent signaling pathways for their neurotrophic and anti-inflammatory effects.
The Role of PPARa in Statin-Induced Expression of Neurotrophic Factors in Glia
Simvastatin inhibits IL-1b-induced mRNA (Figures 2A and 2B) and protein ( Figures 2C and 2D ) expression of iNOS equivalently in wild-type (WT) and Ppara null astrocytes, suggesting that simvastatin does not require PPARa to suppress iNOS. We next examined whether PPARa was involved in statinmediated expression of neurotrophic factors in glia. Interestingly, simvastatin dose-dependently stimulated the mRNA expression of BDNF and NT-3 in WT, but not in Ppara null, microglia (Figures 2E and 2F) and astrocytes (Figures 2G and 2H) . Similarly, simvastatin and pravastatin stimulated the protein expression of BDNF in WT, but not Ppara null, astrocytes ( Figures 2I-2K ) and neurons (Figures S2A and S2B) . Together, these results suggest that PPARa is involved in the statin-mediated upregulation of neurotrophic factors in glia and neurons.
PPARb and PPARg Are Not Involved in Statin-Induced Expression of Neurotrophins Simvastatin was found to stimulate the expression of PPARa, PPARb, and PPARg in astrocytes ( Figure S2C ). Therefore, we next examined the role of PPARb and PPARg in statin-induced expression of BDNF and NT-3. Although activation of PPARg has been shown to induce the expression of BDNF (Jin et al., 2013; Kariharan et al., 2015) , antisense knockdown of PPARg and PPARb failed to inhibit simvastatin-stimulated expression of BDNF and NT-3 in astrocytes ( Figure S2D ), suggesting that neither PPARb nor PPARg is involved in simvastatin-mediated upregulation of neurotrophic factors. However, it is PPARa, but not PPARb, that is involved in statin-mediated upregulation of neurotrophic factors, as simvastatin stimulated BDNF expression in Pparb null astrocytes ( Figure S2E ). The direct involvement of PPARa in the statin-stimulated expression of neurotrophins was further confirmed when simvastatin stimulated the expression of BDNF in PPARa cDNA-, but not empty vector-transfected Ppara null astrocytes (Figures S2F and S2G) . These data suggest that statins require only PPARa for the induction of BDNF and NT-3 in glial cells. Consistent to the role of PPARa in the induction of neurotrophins, prototype ligands of PPARa (WY14643 and gemfibrozil) induced the expression of BDNF and NT-3 in primary astrocytes ( Figure S2H ). Similar to simvastatin, WY14643 and gemfibrozil were also unable to induce the expression of BDNF and NT-3 in Ppara null astrocytes and PPARa overexpression restored the ability of these ligands to induce CREB and neurotrophins in Ppara null astrocytes ( Figure S2I ).
Statins Stimulate the Expression of BDNF and NT-3 In Vivo in Mouse Brain via PPARa Next, we examined whether statins required PPARa ( Figure S3A ) for the upregulation of neurotrophins in vivo in the brain. As evident from RT-PCR ( Figure S3B ) real-time PCR (Figure S3C ), the mRNA expression of both BDNF and NT-3 was significantly higher in WT brain than Ppara null brain. We have shown that both simvastatin and pravastatin are able to cross the bloodbrain barrier (BBB) with variable efficiencies (Ghosh et al., 2009) . Oral administration of both pravastatin (Figures S3D and S3E) and simvastatin ( Figures S3F and S3G ) significantly stimulated the expression of BDNF and NT-3 in vivo in the midbrain of WT, but not Ppara null, mice. However, in accordance with their See also Figure S1 .
BBB permeabilities, simvastatin was more effective than pravastatin in stimulating the expression of neurotrophins in vivo in the brain.
Statins Interact with the Ligand-Binding Domain of PPARa Next, we were prompted to study how statins employ PPARa in the expression of neurotrophic factors. It is not known whether statins are ligands of PPARa. In order to determine whether simvastatin directly interacts with the ligand-binding domain (LBD) of PPARa, simvastatin-treated astrocytic nuclear extracts were pulled down by the PPARa-LBD followed by electrospray ionization tandem mass spectrometry (ESI-MS) analysis. Interestingly, we detected the peak for simvastatin itself in the PPARa-LBD pull-down fraction of simvastatin-treated ( Figures 3B and 3D ), but not control ( Figures 3A and 3C ), astrocytes. Time-resolved fluorescence resonance energy transfer (TR-FRET) is a widely accepted technology for monitoring the physical interaction be- tween protein and ligand spaced at a distance as low as 5 mm. We adopted TR-FRET for analyzing the interaction between PPARa and different statins (Figure 3E) . Our fluorescence dose-response curve clearly indicated that simvastatin ( Figure 3F ), mevastatin ( Figure 3G ), and pravastatin ( Figure 3H ) dose-dependently induced the TR-FRET signal from PPARa-PGC1a complex, suggesting that statins serve as ligand of PPARa. For comparison, we also used atorvastatin and rosuvastatin and found that the signal strength of emitted fluorescence was the highest for simvastatin among simvastatin, mevastatin, pravastatin, atorvastatin, and rosuvastatin (Figure 3I) , suggesting that simvastatin is the strongest ligand of PPARa among different statins. Our observation was further corroborated once we compared EC 50 value of different statins after 30 min of interaction with PPARa. The EC 50 value of simvastatin (4.26) was lower than pravastatin, mevastatin, atorvastatin, and rosuvastatin further suggesting that simvastatin is the strongest ligand of PPARa among different statins. GW7642, a well-known PPARa agonist, displayed similar dose-response curve ( Figure 3F ) under similar condition with much lower EC 50 value (1.11), indicating that the binding affinity of statins to PPARa is still lower than its prototypic ligands.
To characterize the interaction between simvastatin and PPARa in a molecular level, we carried out in silico docking studies of simvastatin with PPARa-LBD. These studies generated a reasonable docked pose of the simvastatin molecule in the ligand-binding pocket ( Figure 4A ). The docked pose of simvastatin showed two potential hydrogen bonds between the statin ligand and two active-site residues, Tyr334 (Y334) and Leu331 (L331) ( Figure 4B ), of the PPARa-LBD. After obtaining a suitable docked pose of the simvastatin, we attempted to compute the apparent binding energy of the ligand along with the strain energy. Using the MM-GBSA approach, we found the binding energy of simvastatin to be -36.0 Kcal/mol with minimal strain energy of 0.71 Kcal/mol, suggesting a strong interaction between simvastatin and PPARa. Imposing the most stringent docking protocols, a reasonable docked pose of simvastatin was obtained for PPARa, with a total score of 8.27, a polar score of 1.54, and a crash score of -0.71. Interestingly, by applying similar docking protocols, we failed to obtain any dock pose of simvastatin for both PPARb and PPARg, suggesting that the interaction of simvastatin with PPARa-LBD is specific and not possible with other PPAR isoforms. However, in silico modeling of protein-ligand interaction is hypothetical and requires rigorous experimental analysis for further validation.
Therefore, we performed lentivirus-mediated de novo expression studies, where we overexpressed wild-type (GFPFLPpara) and statin-binding domain (SBD) mutated PPARa (GFP-DsbdPpara) gene in Ppara null astrocytes followed by the binding analyses with simvastatin. Briefly, we performed site- directed mutagenesis in mouse PPARa gene where we replaced Leu331 residue with methionine (L331M) and Tyr334 residue with aspartate (Y334D). After that, we cloned the entire mouse GFP-Ppara gene and L331M/Y334D Ppara (GFPDsbdPpara) gene in the pLenti6∕V5-TOPO lentiviral expression vector, packaged in lentivirus particle with the help of HEK293FT cells, transduced mouse astrocytes with lentiviral particles for 48 hr, purified full-length (GFP-FLPPARa) and mutated PPARa (GFPDsbdPPARa) proteins in a GFP-affinity column, and finally performed thermal shift assay in order to analyze their conformational stability. Both full-length ( Figure 4C ) and mutated (Figure 4D) proteins displayed similar pattern of thermal shift with equivalent melting temperature (Tm), suggesting that mutations in L331 and Y334 residues did not alter the conformational stability of PPARa. In another experiment, Ppara null astrocytes transduced with different lentiviral PPARa constructs were incubated with simvastatin for 2 hr and then performed ESI-MS analyses in the GFP-affinity purified nuclear fraction of astrocytes. Interestingly, we observed a very specific peak of simvastatin in the nuclear extract of GFP-PPARa (Figures 4Ei and 4Eii ), but neither in empty GFP vector-transduced (Figures 4Eiii and  4Eiv ) nor GFP-DsbdPpara-transduced (Figures 4Ev and 4Evi ) nuclear extracts of astrocytes, suggesting that Leu331 and Tyr334 residues are indeed essential for binding with statin. Next, we examined if these two amino acids were required for statin-mediated activation of PPARa. We measured PPRE-driven luciferase activity in both FLPpara and Dsbd Ppara-transduced Ppara null astrocytes after treatment of simvastatin, mevastatin, and pravastatin. Interestingly, we observed that different statins stimulated PPRE-luciferase activity in FLPpara-transduced, but not in DsbdPpara-transduced, astrocytes ( Figure 4F ), suggesting that statins require these two amino acids for the activation of PPARa.
Next, we investigated if WY14643 and gemfibrozil, classical ligands of PPARa, also required Leu331 and Tyr334 residues for the activation PPARa. Gemfibrozil ( Figure 4G ) and WY14643 ( Figure 4H ) were allowed to dock in the LBD of PPARa using the similar docking protocols used to dock simvastatin. We found that both the compounds docked very nicely with a good docked scores and with very little penalty scores. However, the binding poses of gemfibrozil ( Figure 4G ) and WY14673 ( Figure 4H ) were very different from that of simvastatin. Simvastatin showed potential hydrogen bonds with L331 and Y334 but gemfibrozil and WY14673 were 6 Å and 5 Å away from these residues, suggesting that these two known ligands of PPARa do not interact with L331 and Y334 residues. Consistently, gemfibrozil ( Figure 4I ) and WY14643 ( Figure 4J ) stimulated PPRE-luciferase activity in DsbdPpara-transduced Ppara null astrocytes almost similar to that found FLPpara-transduced cells, confirming that these two ligands do not require L331 and Y334 residues for the activation of PPARa.
Statins Increase CREB via PPARa-Mediated Transcriptional Regulation Different statins ( Figure 5A for mevastatin, pravastatin, and simvastatin; Figure 5B for atorvastatin and rosuvastatin) induced PPARa response element (PPRE)-driven reporter activity, revealing that different statins are capable of activating PPARa in astrocytes. However, detailed analysis of BDNF and NT-3 promoters showed no PPRE, ruling out the direct involvement of PPARa in the upregulation of neurotrophic factors. On the other hand, a number of CRE sequences were found in BDNF and NT-3 promoters. Accordingly, antisense knockdown of CREB suppressed the expression of CREB and inhibited the simvastatin-induced expression of BDNF and NT-3 in mouse astrocytes ( Figure S4A ). Similarly, we observed that CREB siRNA, but not control siRNA, inhibited simvastatin-induced expression of BDNF in astrocytes ( Figure S4B ). These results indicate the involvement of CREB in simvastatin-mediated upregulation of neurotrophic factors.
Although we did not find any PPRE in BDNF and NT-3 promoters, analysis of the CREB promoter revealed the presence of a conserved PPRE (-1,152 to -1,164 bp upstream of the start sequence) prompting us to study the involvement of PPARa in the transcriptional regulation of CREB. Different statins stimulated the expression of CREB mRNA in mouse astrocytes and microglia ( Figure S4C ). However, statins upregulated the expression of CREB mRNA in astrocytes and microglia isolated from WT, but not Ppara null, mice ( Figure S4D ). Immunofluorescence analysis also showed that simvastatin upregulated CREB protein in astrocytes isolated from WT, but not Ppara null, mice (Figure S4E) . Similarly, simvastatin also upregulated the expression of CREB mRNA ( Figure S4F ) and protein ( Figure S4G ) in neurons (A-E) Mouse astrocytes were transfected with PPRE luciferase and after a 24-hr transfection, cells were treated with mevastatin, pravastatin, simvastatin (A), atorvastatin, and rosuvastatin (B) for 4 hr, followed by the luciferase assay. Activation of WT CREB promoter by pravastatin, simvastatin (C), atorvastatin, and rosuvastatin (D) in astrocytes isolated from WT and Ppara null (aKO) mice. Activation of WT and mutated CREB promoter by mevastatin, pravastatin, and simvastatin in mouse astrocytes (E Figure S4H ). Although simvastatin was unable to increase the mRNA expression of CREB in Ppara null neurons, we observed stimulation of CREB mRNA expression by simvastatin in Ppara null neurons after PPARa overexpression ( Figure S4H ). Immunocytochemical analyses also revealed that ectopic overexpression of PPARa in primary human neurons stimulated basal expression of CREB (Figure S4K ) compared with untransfected ( Figure S4I ) or pcDNAtransfected ( Figure S4J ) cells and that simvastatin stimulation further increased the level of CREB in PPARa-overexpressed cells ( Figure S4K ). On the other hand, a dominant-negative mutant of human PPARa (DPPARa) abrogated the expression of CREB, and simvastatin also failed to stimulate the expression of CREB in DPPARa-expressed human neurons ( Figure S4L ).
To further analyze the role of PPARa in the transcription of Creb, we cloned the mouse Creb promoter and then performed site-directed mutagenesis to mutate the PPRE as described (Roy et al., 2013) . Different statins markedly induced Creb promoter-driven luciferase activity in astrocytes isolated from WT, but not Ppara null, mice ( Figure 5C for pravastatin and simvastatin; Figure 5D for atorvastatin and rosuvastatin). However, in WT astrocytes, statins remained unable to induce luciferase activity driven by a Creb promoter in which PPRE was mutated ( Figure 5E ). Next, we performed chromatin immunoprecipitation (ChIP) analysis in which the recruitment of PPARa to the Creb promoter was monitored in untreated and statin-treated astrocytes. After immunoprecipitation of chromatin fragments by antibodies against PPARa, we were able to amplify a 144-bp fragment encompassing the PPRE of the Creb promoter in astrocytes isolated from wild-type, but not Ppara null, mice ( Figures  5F and 5I ). On the other hand, no amplification product of the Creb promoter was observed in any of the immunoprecipitates obtained with PPARb, PPARg, or control IgG ( Figures 5G, 5H , 5J, and 5K), suggesting that PPARa, but neither PPARb nor PPARg, is recruited to the PPRE of the Creb promoter in astrocytes. Both pravastatin ( Figure 5F ) and simvastatin ( Figure 5I ) increased the recruitment of PPARa, but neither PPARb nor PPARg ( Figures 5G, 5H , 5J, and 5K), to the Creb promoter in astrocytes.
Evaluating the Role of Leu331 and Tyr334 of PPARa in the Statin-Induced Expression of BDNF in Cultured Astrocytes and In Vivo in Mouse Brain
Next, we examined if Leu331 and Tyr 334 residues of PPARa were required for statin-mediated upregulation of CREB and BDNF in the cultured astrocytes as well as in vivo in the brain. Mouse primary astrocytes isolated from Ppara null mice were transduced with EGFP-constructed lentiviral particles containing either FLPpara or DsbdPpara. Transduction efficiency was more than 90% for both the constructs ( Figure 6A ). Interestingly, simvastatin significantly upregulated the expression of CREB and BDNF ( Figures 6B and 6C ) in FLPpara-transduced astrocytes, but neither in DsbdPpara-nor empty vector-transduced astrocytes, which we further confirmed by BDNF ELISA from the astroglial supernatants ( Figure 6D ). Since BDNF is the major neurotrophic factor that controls the function of hippocampus, we targeted the hippocampus for lentiviral manipulation of the Ppara gene. GFP-FLPpara and GFP-DsbdPpara lentiviral particles were infused bilaterally in the pyramidal layer of the CA2 region and in the subgranular layer of the dentate gyrus (DG) of 6-to 8-week-old Ppara null mice as described earlier (Roy et al., 2013) . Three weeks after the infusion, we observed a marked distribution of EGFP constructed PPARa in the entire pyramidal (CA1, CA2, and CA3) and DG region ( Figure 6E ), indicating the distribution efficiency of FLPpara and DsbdPpara in our proposed injection coordinates. Simvastatin feeding was started after 6 weeks of lentiviral injection and continued for 2 weeks. Consistent with cell culture results, our immunofluorescence and immunoblot analyses revealed that the bilateral infusion of lentiviral GFP-FLPpara, but neither empty vector nor GFP-DsbdPpara, strongly upregulated the expression of CREB ( Figures 6G and 6H ) and BDNF ( Figures 6F-6I ) in the hippocampus of simvastatin-fed mice, suggesting that both L331 and Y334 residues of PPARa are critical for the statin-mediated upregulation of CREB and BDNF.
Next, we wanted to determine whether the simvastatinmediated upregulation of BDNF production could improve hippocampus-dependent spatial learning and memory in these animals. Therefore, we performed Barnes maze analyses after oral administration of simvastatin (1 mg/kg body weight/day) to FLPpara and DsbdPpara animals for 2 weeks. Since these animals were all on the Ppara null background, they spent similar time before entering into the hole ( Figure 6L ). However, FLPpara mice spent more time in the target quadrant (Q1) after statin feeding when compared to statin-fed Ppara null mice (F 3,28 = 2.87; p % 0.05) or statin-fed DsbdPpara mice (F 3,28 = 3.57; p % 0.05) (Figures 6J and 6K) . Moreover, the number of errors is significantly less in statin-fed FLPpara mice ( Figure 6M ) as compared to statin-fed DsbdPpara (F 3,28 = 3.14; p % 0.05) and statin-fed Ppara null mice (F 3,28 = 13.07; p % 0.01), suggesting that both L331 and Y334 residues of PPARa are crucial for the statin-induced hippocampus-dependent learning and memory.
Validating the PPARa-Mediated Neurotrophic Effect of Statin in FAD5X Mouse Model of AD
In order to analyze the therapeutic importance of PPARa in statin-mediated upregulation of BDNF, we used FAD5X (B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/J) transgenic mouse model of AD. We generated FAD5X mice in the homozygous Ppara null background ( Figure 7A ). Five-month-old non-Tg, FAD5X, Ppara null, and FAD5X/Ppara null mice were fed simvastatin (1 mg/kg body weight/day) for 2 weeks. Interestingly, we observed that simvastatin increased the astroglial expression of BDNF in cortex ( Figures 7B-7E ) of WT ( Figure 7B ) and FAD5X animals ( Figure 7D ), but not in Ppara null ( Figure 7C ) and FAD5X/ Ppara null mice ( Figure 7E ), suggesting that PPARa regulates the expression of BDNF during AD-like pathology. Similarly, our immunoblot ( Figures 7F and 7G ) and ELISA ( Figure 7H ) analyses revealed that both WT and FAD5X, but neither Ppara null nor FAD5X/Ppara null, mice showed upregulated expression of BDNF after simvastatin treatment, suggesting the therapeutic prospect of PPARa in AD. Next, we validated the effect of statin in the process of learning and memory in these animals by analyzing their performance in Barnes maze. Upon simvastatin treatment, both wild-type and FAD5X mice exhibited significant improvement in memory performance on Barnes maze test as shown by errors ( Figure 7I However, Ppara null and FAD5X/Ppara null mice showed no improvement after simvastatin feeding ( Figures 7I and 7J ). Simvastatin treatment did not significantly alter body weight (Figure 7K) , stereotypy ( Figure 7L ), total distance ( Figure 7M ), and horizontal activity ( Figure 7N ) in all groups of mice, suggesting that either simvastatin treatment or genetic alteration do not modulate gross metabolic and motor activities.
DISCUSSION Statins Induce Neurotrophins in Brain Cells
Both BDNF and NT-3 are important for preserving the complex neuronal architecture of hippocampal and cortical circuits. Therefore, increasing the levels of neurotrophins in the CNS is considered to be an important step in halting the progression of several neurodegenerative and neurocognitive diseases.
Because these neurotrophic molecules do not cross the BBB, gene therapy and stereotaxic injection directly into the brain are now the only available options. However, from the therapeutic perspective, it seems that the best option would be to stimulate/induce the production of BDNF and NT-3 in vivo in the CNS of patients with neurodegenerative disorders. Here, we describe the finding that statins are capable of upregulating neurotrophic factors in brain cells and in vivo in the brain. Although previous studies have reported the neurotrophic role of statins in stroke (Chen et al., 2005) and depression (Tsai, 2007) , nothing is known about the role of statins in controlling the expression of neurotrophic factors. According to Tsai (2007) , statins may be involved in the upregulation of plasmin (t-PA) and cleavage of pro-BDNF to mature BDNF. However, this study does not provide any data on the transcriptional upregulation of BDNF by statins.
A Tale of Two Independent Pathways Regulated by Statins
Statins inhibit HMG-CoA reductase, the regulatory enzyme in the cholesterol biosynthesis pathway and thereby lower the level of cholesterol in patients with hypercholesterolemia. However, statins are also anti-inflammatory Pahan et al., 1997) . Although this anti-inflammatory activity of statins is independent of cholesterol, intermediates of the mevalonate pathway abrogate this anti-inflammatory effect (Pahan, 2006; Roy and Pahan, 2011) , and statins employ the isoprenylation-p21 ras /p21 rac pathway to upregulate proinflammatory molecules Roy and Pahan, 2011) . Currently, in addition to cholesterol-lowering, statins are known to inhibit small G protein activation, suppress proinflammatory molecules, modulate the adaptive immune response, stimulate endothelial NOS, attenuate migration and proliferation of smooth muscle cells, lower the production of reactive oxygen species, destabilize amyloid-b fibrils, attenuate a-syn aggregation, and mitigate dyskinesia (Pahan, 2006; Roy and Pahan, 2011; Weber et al., 2005) . In fact, all these functions are dependent on their ability to suppress either intermediates or the end product of the mevalonate pathway. By contrast, here, we have found that metabolites of the cholesterol biosynthetic pathway, including FPP and mevalonate, inhibitors of isoprenoid transferring enzymes (FPTi and GGTi), and dominant-negative mutants of p21 ras and p21 rac , are unable to modulate statin-mediated upregulation of neurotrophic factors, suggesting that statin-mediated inhibition of the cholesterol biosynthetic pathway and/or the isoprenoidp21 ras /p21 rac pathway is/are not involved in the upregulation of neurotrophic factors.
On the other hand, as expected, CREB, a classical transcription factor regulating the synthesis of many neurotrophic factors, was found to be involved in statin-mediated upregulation of neurotrophic factors. Next, we explored the effect of statins on the transcriptional regulation of CREB. Interestingly, promoter analysis of CREB, but not BDNF or NT-3, revealed the presence of a conserved PPRE sequence in its promoter, and we found the involvement of PPARa, but not PPARb or PPARg, in statin-mediated upregulation of CREB and neurotrophic factors. ChIP analysis also showed that simvastatin induced the recruitment of PPARa, but not PPARb or PPARg, to the CREB promoter. Together, our results suggest that statins upregulate neurotrophic factors via a novel PPARa-CREB pathway that is independent of their inhibition of the mevalonate pathway. Therefore, statins employ two distinct pathways to execute their biological functions: suppressing the mevalonate pathway for their previously known biological functions and stimulating the PPARa-CREB pathway for their neurotrophic function (Graphical Abstract).
Apart from neurotrophins, CREB-regulated genes are also involved in the modulation of our basic metabolic processes, including glucose metabolism, fatty acid oxidation, and hepatic lipid mobilization. CREB activates hepatic gluconeogenesis and fatty acid b-oxidation by inducing the expression of PGC-1 and Hes-1 (Herzig et al., 2003) genes. CREB-mediated upregulation of the hepatocyte nuclear factor-4 (HNF-4) gene stimulates the lipid mobilization process in liver (Dell and Hadzopoulou-Cladaras, 1999) . Therefore, downregulation of CREB and many other CREB-regulated genes may contribute to different metabolic disorders, including diabetes, arthritis, and obesity. Thus, the importance of our finding is that statins, one of the most commonly used groups of drugs, may be used to modulate multiple metabolic states via PPARa-mediated upregulation of CREB.
Statins Serve as Ligands of PPARa
For the last 30 years, statins have been widely considered to be competitive inhibitors of HMG-CoA reductase. However, until now there has been no receptor protein identified for statins. Here, we report that PPARa, but not PPARb or PPARg, serves as a receptor for statins. Detailed energy calculations for simvastatin:PPAR complexes shows greater thermodynamic stability of simvastatin:PPARa than either simvastatin:PPARb or simvastatin:PPARg. Our TR-FRET analysis with increasing doses of different statins in PPARa-PGC-1a complex, in silico interaction studies, de novo expression studies of full-length and mutated constructs PPARa followed by ESI-MS analyses, and ESI-MS analysis of PPARa-LBD pull-down from the nuclear fraction confirm the feasibility and stability of the simvastatin: PPARa complex. Among simvastatin, mevastatin, pravastatin, atorvastatin, and rosuvastatin, simvastatin was found to be the strongest ligand of PPARa followed by mevastatin. On the other hand, ligand-binding efficacies of pravastatin, atorvastatin, and rosuvastatin were almost same. According to our detailed structural and molecular techniques, we confirmed that Leu331 and Tyr334 residues of PPARa LBD are important for statin-binding as L331M/Y334D PPARa did not show any interaction with statins. Interestingly, known ligands of PPARa such as WY-14643 and gemfibrozil did not show interaction with Leu331 and Tyr334 residues. While WY-14643 and gemfibrozil docked nicely at the ligand-binding pocket, these ligands were 6 Å and 5 Å away from Leu331 and Tyr334 residues and mutation of these residues also did not abrogate the ability of these ligands to activate PPARa. These results identify statins as a different group of PPARa ligands that differ from classical ligands in terms of binding to the PPARa LBD. Since PPARa plays an important role in fatty acid oxidation, lipoprotein metabolism, and peroxisome proliferation (Pahan, 2006) , our present finding suggests that statins may also regulate these biological processes via PPARa.
Simvastatin Increases BDNF and Improves Memory in an Animal Model of AD via PPARa Simvastatin treatment increased BDNF in hippocampus and cortex and improved memory and learning in the FAD5X mouse model of AD. In contrast, simvastatin remained unable to stimulate BDNF in CNS tissues and increase memory and learning in FAD5X/Ppara null mice, suggesting a critical role of PPARa in the upregulation of neurotrophins in the CNS and protection of memory during AD pathology. Since upregulation of BDNF in the hippocampus and the cortex has therapeutic potential for AD, simvastatin may be beneficial for AD. However, a number of evidences from randomized clinical trials using simvastatin consistently report no benefit in cognition or dementia prevention (Sano et al., 2011; Stadelmann et al., 2002) . In some cases, studies failed to provide clear evidence for its therapeutic efficacy in AD (Burgos et al., 2012) , calling into question the relevance of preclinical and epidemiologic findings. Again, decreased neuronal cholesterol synthesis has been implicated as a contributor to neurodegeneration (Karasinska and Hayden, 2011; Liu et al., 2010; Valenza et al., 2010) and impaired CNS function in the context of diabetes/insulin resistance (Suzuki et al., 2010) . Here, our findings disclose a new site of action (PPARa) for statin that could be predictive of therapeutic benefit in AD patients. However, a recent study indicates that women with high level of LDL cholesterol show increased loss of visual memory when prescribed with fenofibrate, a known ligand of PPARa, over 7 years (Ancelin et al., 2012) . This may be due to the facts that higher LDL cholesterol is associated with better memory functioning among the elderly without ApoE4 allele (West et al., 2008) and that long-term use of fenofibrate affects visual memory via reducing LDL cholesterol. Therefore, the relevance of the statin-PPARa-CREB connection in humans remains to be established.
EXPERIMENTAL PROCEDURES
Isolation of Mouse Primary Astroglia and Microglia
Microglia and astroglia were isolated from mixed glial cultures of 7-day-old mouse pups according to the procedure of Giulian and Baker (1986) as described earlier (Dasgupta et al., 2003; Roy et al., 2006) .
Isolation of Human Fetal Neurons
Primary human neurons were isolated from human fetal brain tissues as described by us earlier Pahan, 2004a, 2004b) . All of the experimental protocols were reviewed and approved by the Institutional Review Board of the Rush University Medical Center.
Transfection of Neurons
Primary neurons were transfected with Lipofectamine PLUS (Invitrogen) and Nupherin-neuron (Biomol) as described by us earlier (Saha and Pahan, 2007) . Briefly, each well of 6-well plate was transfected with 0.25 mg of DNA complexed with Neupherin peptide and Lipofectamine PLUS.
ChIP ChIP was performed as described earlier (Roy et al., 2013) .
RT-PCR Analysis
Total RNA was digested with DNase and RT-PCR was carried out as described earlier (Ghosh et al., 2009; Roy et al., 2013) .
Real-Time PCR Analysis
Quantitative real-time PCR was performed in the ABI-7500 standard PCRs (Applied Biosystems) as described earlier (Ghosh et al., 2009; Roy et al., 2013) using TaqMan Universal Master mix and FAM-labeled probes and primers (Applied Biosystems).
Cloning of the Creb Promoter and Site-Directed Mutagenesis CREB promoter was cloned and subjected to site-directed mutagenesis as described earlier (Roy et al., 2013) .
Lentiviral Cloning of FL PPARa and L331M/Y334D PPARa
Please see the Supplemental Experimental Procedures.
Lentiviral Administration of FLPPARa and DPPARa in the Adult Mouse Hippocampus
Lentiviral administration was performed as described earlier (Roy et al., 2013) . TR-FRET Analysis TR-FRET was performed using Lanthascreen TR-FRET PPAR-alpha coactivator assay kit. In this assay, statins were incubated with GST-tagged recombinant PPARa LBD, Terbium (Tb)-tagged anti GST antibody, and fluorescein (FL)-tagged PGC-1a as directed in the manufacturer's protocol. The entire reaction was set up in corning 384-well plate by an automated robotic injector. Plate was centrifuged, incubated in dark for 30 min, and then analyzed in molecular devices analyst equipped with dichroic mirror. The excitation and emission were set at 340 nm and 540 nm, respectively.
Thermal Shift Assay
Thermal shift assay was performed in Applied Biosystems 7500 standard realtime thermal cycler with thermal shift dye kit (Life Technologies). For each reaction, purified protein (0.5 mg to 1 mg) was added to 18 ml of thermal shift buffer and 1-2 ml of dye. Reaction was set 96-well PCR plate in dark and then placed in the thermal cycler using the following two-stage program ([25 C for 2 min] 1 cycle; [27 C for 15 s, 26 C for 1 min] 70 cycles; auto increment 1 C for both stages). The filter was set at ROX with no quencher filter and no passive filter.
Statistical Analyses
All values are expressed as the mean ± SD. Differences among means were analyzed using one-or two-way ANOVA with time or genotype as the independent factors. Differences in behavioral measures were examined by independent one-way or repeated-measures ANOVAs using SPSS. Homogeneity of variance between test groups was examined using Levene's test. Post hoc analyses of between-subjects effects were conducted using Scheffe's, Tukey's or Games-Howell tests, where appropriate. p < 0.05 was considered statistically significant. .001 vs control not significant vs KO control. (B) WT and Ppara null neurons were stimulated with 5 µM simvastatin or pravastatin under serum free condition. After 24 h, cells were double-labeled for BDNF and MAP-2. Results represent three independent experiments. C) Mouse primary astrocytes were treated with different doses of simvastatin for 5 h followed by analysis of PPAR,  and  mRNAs by RT-PCR. D) Mouse astrocytes were incubated with PPARβ and γ antisense oligoneucleotides (AsO) for 24 h. After that, cells were incubated with 10 µM of simvastatin for 5 h followed by mRNA analysis of BDNF, NT3, PPARα, PPARβ, and PPARγ by semiquantitative RT-PCR. Scrambled oligoneucleotide (ScO) were used as a negative control in this experiment. E) Astrocytes isolated from Pparb null mice were stimulated with simvastatin under serum-free condition for 24 h followed by double-label immunofluorescence for GFAP and BDNF. Ppara null astrocytes were transfected with pcDNA3 (an empty vector) or Ppara over-expression construct. After 24 h, cells were stimulated with different doses of simvastatin for 5 h followed by mRNA analysis of BDNF and NT-3 by RT-PCR (F) and real-time PCR (G). Data are mean ± SD of three independent experiments. 
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